EQUITAS HEALTH: Equitas Health, Prism Health North Texas Announce New Partnership to Increase Access to Affordable Prescription Drug

Ohio-based Equitas Health and Dallas-based Prism Health North Texas (PHNTX) announced today a new partnership that forms an integrated care model that will serve to further address challenges patients in North Texas experience when needing access to expensive life-saving prescription drugs like those used to treat HIV infection. Read More »

REGENERON PHARMACEUTICALS, INC.: CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab), recommending to extend its approval in the European Union (EU) to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Read More »